Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Discharged but not dissatisfied: outcomes and satisfaction of patients discharged from the Edinburgh Trauma Triage Clinic.

Mackenzie SP, Carter TH, Jefferies JG, Wilby JBJ, Hall P, Duckworth AD, Keating JF, White TO.

Bone Joint J. 2018 Jul;100-B(7):959-965. doi: 10.1302/0301-620X.100B7.BJJ-2017-1388.R2.

PMID:
29954208
2.

Infographic: Trauma Triage Clinic reduces unnecessary fracture clinic attendances and costs with comparable clinical outcomes.

Mackenzie SP, Carter TH, Jefferies JG, Wilby JBJ, Hall P, Duckworth AD, Keating JF, White TO.

Bone Joint J. 2018 Jul;100-B(7):957-958. doi: 10.1302/0301-620X.100B7.BJJ-2018-0623. No abstract available.

PMID:
29954201
3.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.

Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4641-E4647. doi: 10.1073/pnas.1703142114. Epub 2017 May 22.

4.

The evolution of fracture clinic design : the activity and safety of the Edinburgh Trauma Triage Clinic, with one-year follow-up.

White TO, Mackenzie SP, Carter TH, Jefferies JG, Prescott OR, Duckworth AD, Keating JF.

Bone Joint J. 2017 Apr;99-B(4):503-507. doi: 10.1302/0301-620X.99B4.BJJ-2016-0870.R1.

PMID:
28385940
5.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-84. doi: 10.1073/pnas.1422050112. Epub 2014 Dec 15.

6.

A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.

Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G.

PLoS One. 2014 Oct 6;9(10):e108694. doi: 10.1371/journal.pone.0108694. eCollection 2014.

7.

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD.

Leukemia. 2015 Mar;29(3):567-75. doi: 10.1038/leu.2014.267. Epub 2014 Sep 10.

8.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.

Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD.

Leukemia. 2014 Aug;28(8):1754-1758. doi: 10.1038/leu.2014.114. Epub 2014 Mar 21. No abstract available.

9.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CD.

J Clin Oncol. 2014 Feb 20;32(6):548-56. doi: 10.1200/JCO.2013.50.6337. Epub 2013 Dec 30.

10.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.

Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD.

Leukemia. 2014 Jun;28(6):1252-1258. doi: 10.1038/leu.2013.371. Epub 2013 Dec 11.

11.

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.

Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD.

Leukemia. 2013 Oct;27(10):2023-31. doi: 10.1038/leu.2013.181. Epub 2013 Jun 14.

12.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.

Mendler JH, Maharry K, Becker H, Eisfeld AK, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, Bloomfield CD.

Haematologica. 2013 Aug;98(8):e92-4. doi: 10.3324/haematol.2013.089904. Epub 2013 Jun 10. No abstract available.

13.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2.

14.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD.

Blood. 2012 Jul 12;120(2):249-58. doi: 10.1182/blood-2012-02-408492. Epub 2012 Apr 23.

15.

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.

Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD.

Leukemia. 2012 Jul;26(7):1713-7. doi: 10.1038/leu.2012.34. Epub 2012 Feb 7. No abstract available.

16.

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2012 Mar 1;30(7):742-50. doi: 10.1200/JCO.2011.39.2092. Epub 2012 Jan 30.

17.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

Blood. 2011 Dec 22;118(26):6920-9. doi: 10.1182/blood-2011-08-368225. Epub 2011 Oct 26.

18.

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD.

Haematologica. 2011 Oct;96(10):1488-95. doi: 10.3324/haematol.2011.041905. Epub 2011 Jun 9.

19.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22.

20.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD.

Blood. 2010 Dec 16;116(25):5660-9. doi: 10.1182/blood-2010-06-290536. Epub 2010 Sep 14.

21.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

Blood. 2010 Nov 4;116(18):3622-6. doi: 10.1182/blood-2010-05-283648. Epub 2010 Jul 23.

22.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD.

Blood. 2010 Aug 5;116(5):788-92. doi: 10.1182/blood-2010-01-262543. Epub 2010 May 4.

23.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

24.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496. Epub 2009 Dec 21.

25.

Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane.

Savino JA 3rd, Evans JF, Rabinowitz D, Auborn KJ, Carter TH.

Mol Cancer Ther. 2006 Mar;5(3):556-63.

26.

Apoptosis in cervical cancer cells: implications for adjunct anti-estrogen therapy for cervical cancer.

Chen D, Carter TH, Auborn KJ.

Anticancer Res. 2004 Sep-Oct;24(5A):2649-56.

27.

Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro.

Sun S, Han J, Ralph WM Jr, Chandrasekaran A, Liu K, Auborn KJ, Carter TH.

Cell Stress Chaperones. 2004 Mar;9(1):76-87.

28.

Indole-3-carbinol is a negative regulator of estrogen.

Auborn KJ, Fan S, Rosen EM, Goodwin L, Chandraskaren A, Williams DE, Chen D, Carter TH.

J Nutr. 2003 Jul;133(7 Suppl):2470S-2475S. Review.

PMID:
12840226
29.

Diindolylmethane alters gene expression in human keratinocytes in vitro.

Carter TH, Liu K, Ralph W Jr, Chen D, Qi M, Fan S, Yuan F, Rosen EM, Auborn KJ.

J Nutr. 2002 Nov;132(11):3314-24.

PMID:
12421845
30.

The influence of health insurance on outcomes of related-donor hematopoietic stem cell transplantation for AML and CML.

Selby GB, Ali LI, Carter TH, Veseley S, Roy V.

Biol Blood Marrow Transplant. 2001;7(10):576. No abstract available.

PMID:
11760090
33.

Treatment of human papillomavirus gynecologic infections.

Auborn KJ, Carter TH.

Clin Lab Med. 2000 Jun;20(2):407-22. Review.

PMID:
10863647
34.

Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation.

Abang AM, Takemoto MH, Pham T, Mandanas RA, Roy V, Selby GB, Carter TH.

Anticancer Drugs. 2000 Feb;11(2):137-42.

PMID:
10789597
35.

The role of community review in evaluating the risks of human genetic variation research.

Foster MW, Sharp RR, Freeman WL, Chino M, Bernsten D, Carter TH.

Am J Hum Genet. 1999 Jun;64(6):1719-27.

36.

Marrow and stem cell transplantation in Oklahoma: fifteen years of experience and results.

Mandanas RA, Carter TH, Epstein RB, Roy V, Selby GB.

J Okla State Med Assoc. 1998 Sep;91(6):339-46.

PMID:
9763768
37.

A model agreement for genetic research in socially identifiable populations.

Foster MW, Bernsten D, Carter TH.

Am J Hum Genet. 1998 Sep;63(3):696-702.

38.

Communal discourse as a supplement to informed consent for genetic research.

Foster MW, Eisenbraun AJ, Carter TH.

Nat Genet. 1997 Nov;17(3):277-9.

PMID:
9354789
39.
40.

Autoantibodies that stabilize the molecular interaction of Ku antigen with DNA-dependent protein kinase catalytic subunit.

Satoh M, Ajmani AK, Stojanov L, Langdon JJ, Ogasawara T, Wang J, Dooley MA, Richards HB, Winfield JB, Carter TH, Reeves WH.

Clin Exp Immunol. 1996 Sep;105(3):460-7.

41.

The DNA-activated protein kinase -- DNA-PK.

Anderson CW, Carter TH.

Curr Top Microbiol Immunol. 1996;217:91-111. No abstract available.

PMID:
8787620
42.

Human DNA-activated protein kinase (DNA-PK) is homologous to phosphatidylinositol kinases.

Poltoratsky VP, Shi X, York JD, Lieber MR, Carter TH.

J Immunol. 1995 Nov 15;155(10):4529-33.

PMID:
7594449
43.

Resistance to transformation by insertionally activated c-erbB is a dominant phenotype in fibroblasts.

Carter TH, Dominguez N, Zeng L, Kung HJ.

Virology. 1995 Sep 10;212(1):277-83.

44.

In vivo and in vitro phosphorylation of the human estrogen receptor.

Arnold SF, Obourn JD, Yudt MR, Carter TH, Notides AC.

J Steroid Biochem Mol Biol. 1995 Feb;52(2):159-71.

PMID:
7873451
45.

Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor.

Carter TH, Kung HJ.

Crit Rev Oncog. 1994;5(4):389-428. Review.

PMID:
7711115
46.
47.

Phosphorylation of protein tau by double-stranded DNA-dependent protein kinase.

Wu JM, Chen Y, An S, Perruccio L, Abdel-Ghany M, Carter TH.

Biochem Biophys Res Commun. 1993 May 28;193(1):13-8.

PMID:
8503898
48.

Activation of protein kinase C inhibits adenovirus VA gene transcription in vitro.

James CB, Carter TH.

J Gen Virol. 1992 Dec;73 ( Pt 12):3133-9.

PMID:
1469352
49.

Chicken progesterone receptor is phosphorylated by a DNA-dependent protein kinase during in vitro transcription assays.

Weigel NL, Carter TH, Schrader WT, O'Malley BW.

Mol Endocrinol. 1992 Jan;6(1):8-14.

PMID:
1738374
50.

Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation.

Kung HJ, Boerkoel C, Carter TH.

Curr Top Microbiol Immunol. 1991;171:1-25. Review. No abstract available.

PMID:
1814689

Supplemental Content

Loading ...
Support Center